Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

NCT06954116 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)
PROCEDURE: Partial hepatectomy

Sponsor

Tongji Hospital

Collaborators

[object Object]